Condition
Post-COVID
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 3 (1)
Trial Status
Completed1
Recruiting1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT05238415Not ApplicableCompleted
ASAP - Assisted Immediate Augmented Post-/Long-COVID Plan for Patients Infected With COVID-19
NCT07359482Phase 3Not Yet RecruitingPrimary
sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19
NCT06897553Not ApplicableRecruiting
ACT for Mental Health in Neurological Disorders
Showing all 3 trials